This function calculates the ‘empiric’ power of group sequential 2-stage BE in 2<U+00D7>2 crossover designs via simulations. The number of subjects in both stages has to be prespecified (non-adaptive).
power.tsd.GS(alpha = c(0.0294, 0.0294), n, CV, theta0, theta1, theta2,
fCrit = c("CI", "PE"), fClower, fCupper, nsims, setseed = TRUE,
details = FALSE)
Vector of the two nominal alpha values to be used in the
confidence interval calculations in the two stages.
Use something like package ldbounds
for choosing the nominal alphas.
Vector of the two sample sizes in
and . n(total)
is n[1]+n[2]
if a second stage is necessary. Otherwise it is n[1]
.
Coefficient of variation of the intra-subject variability (use e.g., 0.3 for 30%).
Assumed ratio of geometric means (T/R) for simulations. If missing, defaults to 0.95.
Lower bioequivalence limit. Defaults to 0.80.
Upper bioequivalence limit. Defaults to 1.25.
Futility criterion.
If set to "PE"
the study stops after
if not BE and if the point
estimate (PE) of evaluation
is outside the range defined in the next two arguments "fClower"
and
"fCupper"
.
If set to "CI"
the study stops after
if not BE and if the 90% confidence interval of
evaluation is outside the range
defined in the next two arguments.
Defaults to "CI"
.
Lower limit of the futility criterion. Defaults to 0
if missing,
i.e., no futility criterion.
Upper limit of the futility criterion. Defaults to 1/fClower
if missing.
Number of studies to simulate.
If missing, nsims
is set to 1E+05 = 100,000 or to 1E+06 = 1 Mio if
estimating the empiric Type I Error ('alpha'
), i.e., with theta0
at the border or outside the acceptance range theta1
… theta2
.
Simulations are dependent on the starting point of the (pseudo) random number
generator. To avoid differences in power for different runs a
set.seed(1234567)
is issued if setseed=TRUE
, the default.
Set this argument to FALSE
to view the variation in power between
different runs.
If set to TRUE
the function prints the results of time measurements
of the simulation steps. Defaults to FALSE
.
Returns an object of class "pwrtsd"
with all the input arguments and results
as components.
The class "pwrtsd"
has a S3 print method.
The results are in the components:
Fraction of studies found BE.
Fraction of studies found BE in .
Percentage of studies continuing to .
The calculations follow in principle the simulations as described in Potvin et al. for adaptive designs, but with no interim power inspection and pre-specified (fixed) number of subjects in . The underlying subject data are assumed to be evaluated after log-transformation. But instead of simulating subject data, the statistics pe1, mse1 and pe2, SS2 are simulated via their associated distributions (normal and distributions).
Gould AL. Group sequential extensions of a standard bioequivalence testing procedure. J Pharmacokin Biopharm. 1995; 23(1):57--86 10.1007/BF02353786
Patterson SD, Jones B. Bioequivalence and Statistics in Clinical Pharmacology. Boca Raton: CRC Press; 2 edition 2016. Chapter 5.6 Optional Designs.
Sch<U+00FC>tz H. Two-stage designs in bioequivalence trials. Eur J Clin Pharmacol. 2015; 71(3):271--81. 10.1007/s00228-015-1806-2
Kieser M, Rauch G. Two-stage designs for cross-over bioequivalence trials. Stat Med. 2015; 34(16):2403--16. 10.1002/sim.6487
Zheng Ch, Zhao L, Wang J. Modifications of sequential designs in bioequivalence trials. Pharm Stat. 2015; 14(3):180--8. 10.1002/pst.1672
power.tsd
and power.tsd.p
for adaptive sequential designs.
# NOT RUN {
# using the Pocock alpha settings and no futility rule
# (defaults), a CV of 20% and 12 subjects in both stages,
# midway interim
power.tsd.GS(CV=0.2, n=c(12,12))
# }
Run the code above in your browser using DataLab